NEW YORK, June 1, 2017 /PRNewswire/ --
Today, Stock-Callers.com redirects investors' attention to the Major DrugManufacturers industry, which includes companies that develop and sell medicines and vaccines for a wide range of medical uses. Lined up for evaluation this morning are: AstraZeneca PLC (NYSE: AZN), Bristol-Myers Squibb Co. (NYSE: BMY), Eli Lilly and
On Wednesday, shares in Cambridge, the UK headquartered AstraZeneca PLC rose 1.12%, ending the day at $34.39. The stock recorded a trading volume of 3.70 million shares. The Company's shares have advanced 13.61% in the last one month, 17.29% over the previous three months, and 25.88% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 9.37% and 14.21%, respectively. Moreover, shares of AstraZeneca, which engages in the discovery, development, manufacture, and commercialization of prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, infection, gastrointestinal, and neuroscience diseases worldwide, have a Relative Strength Index (RSI) of 69.93.
On May 12th, 2017, research firm Credit Suisse upgraded the Company's stock rating from 'Underperform' to 'Neutral'.
On May 26th, 2017, AstraZeneca, along with its global biologics R&D arm MedImmune, announced that the Company will demonstrate how it is rapidly delivering on its science-led strategy for transformational cancer medicine development at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago, IL from June 02nd, 2017, to June 06th, 2017. AZN complete research report is just a click away and free at:
Shares in New York headquartered Bristol-Myers Squibb Co. ended the day 0.04% higher at $53.95 with a total trading volume of 8.15 million shares. The stock is trading below its 50-day moving average by 1.07%. Shares of the Company, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 43.16.
On May 30th, 2017, Bristol-Myers Squibb and Advaxis, Inc. announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment option for women with metastatic cervical cancer. The complimentary report on BMY can be downloaded at:
At the close of trading on Wednesday, shares in Indianapolis, Indiana headquartered Eli Lilly and Co. finished 1.56% higher at $79.57. A total volume of 5.17 million shares was traded, which was above their three months average volume of 3.91 million shares. The stock has advanced 8.18% on an YTD basis. The Company's shares are trading above their 200-day moving average by 1.41%. Additionally, shares of Eli Lilly, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 47.73.
On May 24th, 2017, Elanco Animal Health, a division of Eli Lilly, announced that it received a grant from the Bill & Melinda Gates Foundation to provide sustainable development solutions to address food insecurity in East African countries. The commitment will work to improve animal health and productivity in dairy herds and poultry flocks for smallholder farms in Kenya, Uganda, and Tanzania. Sign up for your complimentary research report on LLY at:
Paris, France headquartered Sanofi's shares recorded a trading volume of 937,974 shares at the end of yesterday's session. The stock closed the day 1.08% higher at $49.59. The Company's shares have advanced 4.93% in the past month, 14.05% in the previous three months, and 22.63% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 5.97% and 18.51%, respectively. Additionally, shares of Sanofi, which researches, develops, manufactures, and markets therapeutic solutions, have an RSI of 61.86.
On May 11th, 2017, research firm Berenberg downgraded the Company's stock rating from 'Buy' to 'Hold'.
On May 22nd, 2017, Sanofi and Regeneron Pharmaceuticals, Inc. announced the US FDA's approval of Kevzara® (sarilumab) for the treatment of adult patients with moderately-to-severely-active rheumatoid arthritis, who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs, such as methotrexate. Kevzara is a human, monoclonal antibody that binds to the interleukin-6 receptor (IL-6R), and that has been shown to inhibit IL-6R mediated signaling. Get free access to your research report on SNY at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: firstname.lastname@example.org Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All